

E2 1 THIOLUTIN/CN
 E3 0 --> THIOLUTIN DIOXIDE/CN
 E4 1 THIOLUX/CN
 E5 1 THIOLYSINE COMPLEX/CN
 E6 1 THIOLYTE BB/CN
 E7 1 THIOLYTE MB/CN
 E8 1 THIOLYTE MC/CN
 E9 1 THIOLYTE MQ/CN
 E10 1 THIOMAG/CN
 E11 1 THIOMAGNETITE/CN
 E12 1 THIOMAGNETITE (FE3O3S)/CN

=> s e2

L1 1 THIOLUTIN/CN

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS

RN 87-11-6 REGISTRY

CN Acetamide, N-(4,5-dihydro-4-methyl-5-oxo-1,2-dithiolo[4,3-b]pyrrol-6-yl) -
 (8CI, 9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1,2-Dithiolo[4,3-b]pyrrol-5(4H)-one, 6-acetamido-4-methyl- (6CI, 7CI)

CN 1,2-Dithiolo[4,3-b]pyrrole, acetamide deriv.

OTHER NAMES:

CN 3-Acetamido-5-methylpyrrolin-4-one[4,3-d]-1,2-dithiole

CN Acetopyrrothin

CN N-(4,5-Dihydro-4-methyl-5-oxo-1,2-dithiolo[4,3-b]pyrrol-6-yl)acetamide


CN **Thiolutin**

FS 3D CONCORD

MF C8 H8 N2 O2 S2

LC STN Files: AGRICOLA, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO,
 CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CSCHEM,
 DDFU, DRUGU, EMBASE, MEDLINE, MRCK*, NAPRALERT, RTECS*, TOXCENTER,
 USPATFULL

(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

78 REFERENCES IN FILE CA (1962 TO DATE)

78 REFERENCES IN FILE CAPLUS (1962 TO DATE)

28 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> FIL CAPLUS BIOSIS MEDLINE USPATFULL WPIDS

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 07:39:12 ON 03 MAR 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 07:39:12 ON 03 MAR 2003

FILE 'USPATFULL' ENTERED AT 07:39:12 ON 03 MAR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 07:39:12 ON 03 MAR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

=> s l1 or thiolutin
L2 240 L1 OR THIOLUTIN

=> s CNS or nerve? or nervous
L3 1969052 CNS OR NERVE? OR NERVOUS

=> s l2 and l3
L4 5 L2 AND L3

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5 4 DUP REM L4 (1 DUPLICATE REMOVED)

=> d ab bib tot

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 1
AB The present invention relates to the use of **thiolutin** dioxide
(I) and its derivs. in the manufacture of a medicament for the treatment of
CNS disorders, to a process for the production thereof by fermentation of
the microorganism Nocardiosis species ST 100692, DSM 13834 , and to the
micro-organism Nocardiosis species ST 100692, DSM 13834. Above
microorganisms were cultured to obtain I. The IC 50 of I as neurolysin
inhibitor was 0.6 M.
AN 2002:693119 CAPLUS
DN 137:222003
TI Use of **thiolutin** dioxide and its derivatives for the treatment
of **CNS** disorders and a process for the preparation thereof
IN Eder, Claudia; Kurz, Michael; Wink, Joachim
PA Aventis Pharma Deutschland GmbH, Germany
SO Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1238668	A1	20020911	EP 2001-105959	20010309
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2002072089	A2	20020919	WO 2002-EP1915	20020223
WO 2002072089	A3	20021114		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

US 2002193418 A1 20021219 US 2002-92882 20020308
PRAI EP 2001-105959 A 20010309
OS MARPAT 137:222003
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 4 USPATFULL
AB The present invention relates to the use of **thiolutin** dioxide and its derivatives in the manufacture of a medicament. Such medicaments are useful, for example, in the treatment of **CNS** disorders. The present invention also relates to a process for the production of **thiolutin** dioxide and its derivatives by fermentation of microorganisms, such as the microorganism *Nocardioopsis* species ST 100692 (DSM 13834).
AN 2002:338051 USPATFULL
TI Methods of using and preparing **thiolutin** dioxide
IN Eder, Claudia, Hofheim, GERMANY, FEDERAL REPUBLIC OF
Kurz, Michael, Hofheim, GERMANY, FEDERAL REPUBLIC OF
Wink, Joachim, Rodermark, GERMANY, FEDERAL REPUBLIC OF
PI US 2002193418 A1 20021219
AI US 2002-92882 A1 20020308 (10)
PRAI EP 2001-105959 20010309
DT Utility
FS APPLICATION
LREP Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 437
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 4 USPATFULL
AB Gas and gaseous precursor filled microspheres, and foams thereof, provide novel topical and subcutaneous delivery vehicles for various active ingredients, including drugs and cosmetics.
AN 1998:33606 USPATFULL
TI Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
IN Unger, Evan C., Tucson, AZ, United States
Matsunaga, Terry O., Tucson, AZ, United States
Yellowhair, David, Tucson, AZ, United States
PA ImaRx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)
PI US 5733572 19980331
AI US 1994-346426 19941129 (8)
RLI Continuation-in-part of Ser. No. US 1994-307305, filed on 16 Sep 1994
Ser. No. Ser. No. US 1993-159687, filed on 30 Nov 1993, now patented, Pat. No. US 5585112 Ser. No. Ser. No. US 1993-160232, filed on 30 Nov 1993, now patented, Pat. No. US 5542935 And Ser. No. US 1993-159674, filed on 30 Nov 1993, now abandoned, said Ser. No. US -159687 Ser. No. Ser. No. US -160232 And Ser. No. US -159674, each Ser. No. US - which is a continuation-in-part of Ser. No. US 1993-76239, filed on 11 Jun 1993, now patented, Pat. No. US 5469854 And Ser. No. US 1993-76250, filed on 11 Jun 1993, now patented, Pat. No. US 5580575, said Ser. No. US -76239 And Ser. No. US -76250, each Ser. No. US - which is a continuation-in-part of Ser. No. US 1991-717084, filed on 18 Jun 1991, now patented, Pat. No. US 5228446 And Ser. No. US 1991-716899, filed on 18 Jun 1991, now abandoned, said Ser. No. US -717084 And Ser. No. US

EXAM Primary Examiner: RISHORE, GOLLAMUDI S.
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 4174
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS
AB Trunk injections with oligomycin (400-800 ppm.), phytoactin (100 ppm.), cycloheximide (25 ppm.), 2-mercaptobenzothiazole (1000 ppm.), BzOH (1000 ppm.), indole-3-acetic acid (1000 ppm.), and Na azide (100 ppm.) prolonged the incubation period of the oak wilt disease (*Ceratocystis fagacearum*) by 3 weeks to 12 months in northern pin oaks. Soil drenches also extended the incubation periods, but foliage sprays were relatively ineffective. Basal trunk spray applications of cycloheximide (1600 ppm.), cycloheximide acetate (3200 ppm.), and cycloheximide semicarbazone (1200 ppm.) in fuel oil also reduced disease development. However, none of the antibiotics or chemicals tested completely controlled the oak wilt disease.
AN 1966:510018 CAPLUS
DN 65:110018
OREF 65:20520g-h,20521a
TI A field evaluation of antibiotics and chemicals for control of oak wilt in northern pin oaks (*Quercus ellipsoidalis*)
AU Phelps, William R.; Kuntz, J. E.; Ross, Arnold
CS North Central States Forest Expt. Sta., Rhinelander, WI
SO Plant Dis. Rep. (1966), 50(10), 736-9
DT Journal
LA English

=> s nocardiosis

L6 590 NOCARDIOPSIS

=> d his

(FILE 'HOME' ENTERED AT 07:37:29 ON 03 MAR 2003)

FILE 'REGISTRY' ENTERED AT 07:37:38 ON 03 MAR 2003
E THIOLUTIN DIOXIDE/CN

L1 1 S E2

FILE 'CAPLUS, BIOSIS, MEDLINE, USPATFULL, WPIDS' ENTERED AT 07:39:12 ON 03 MAR 2003

L2 240 S L1 OR THIOLUTIN
L3 1969052 S CNS OR NERVE? OR NERVOUS
L4 5 S L2 AND L3
L5 4 DUP REM L4 (1 DUPLICATE REMOVED)
L6 590 S NOCARDIOPSIS

=> s l2 and l6

L7 3 L2 AND L6

=> d ti tot

L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS
TI Use of **thiolutin** dioxide and its derivatives for the treatment of CNS disorders and a process for the preparation thereof

central nervous system disorders, e.g. Parkinson's disease, Alzheimer's disease or schizophrenia.